Research information, not medical advice. This page summarises published evidence and registered trials so that you can look further; it does not assess your situation. Talk to your own clinician before acting on anything here. How we select and grade sources
Based on: Hypertension — gene targets, candidate compounds and trials, OSMF Research Tracker (DGIdb, Open Targets, ChEMBL, PubMed and ClinicalTrials.gov data). Numbers are a snapshot taken 28 October 2026; the tracker page is the live version.
Full trial data → The Hypertension pipeline page on the Research Tracker has every candidate, gene target and trial, with evidence grades.
Short answer: as of October 2026, the OSMF Research Tracker lists 46 candidate medicines for hypertension that are either approved medicines or have at least one registered clinical trial, built on 13 druggable gene targets, with 15 recent trials on ClinicalTrials.gov. 6 are already approved medicines, for this condition or another one; where the approval is for a different condition, the trial is testing a new use, which is what drug repurposing means. Being in a trial says an intervention is being studied, not that it works; that is what the trial is for.
Which candidates have the most trial activity?
Ranked by the number of registered trials the tracker found. Each trial ID links to the registry entry, where you can read the design, status and sponsor.
- Azilsartan — 2 registered trials · approved medicine · NCT02079805 NCT02100319
- sibutramine — 2 registered trials · in clinical trials · NCT00679653
- Chlorthalidone — 1 registered trial · approved medicine · NCT00241839
- cilnidipine — 1 registered trial · approved medicine · NCT00325637
- Labetalol — 1 registered trial · approved medicine · NCT01912677
- Methyldopa — 1 registered trial · approved medicine · NCT01912677
- Telmisartan — 1 registered trial · approved medicine · NCT02079805
- 1 dose of Beetroot juice intake — 1 registered trial · in clinical trials · NCT06584331
- 2 doses of Beetroot juice intake — 1 registered trial · in clinical trials · NCT06584331
- 24-hour ambulatory blood pressure monitor — 1 registered trial · in clinical trials · NCT05866445
- alagebrium (ALT-711) — 1 registered trial · in clinical trials · NCT00045981
- Ali/Amlo 150/2.5 mg — 1 registered trial · in clinical trials · NCT01237873
Which gene targets are these built on?
The tracker starts from genes with evidence of being druggable in hypertension and asks which compounds act on them. Each symbol links to its DGIdb entry, which lists the interacting drugs and the papers behind them: ACE, ADRB1, ADRB2, AGT, AGTR1, AGTR2, CACNA1C, EDN1, NOS3, NPR1, NR3C2, REN, SLC12A3.
Which trials are registered?
Drug and biologic treatment trials whose main condition is hypertension, from the tracker's ClinicalTrials.gov snapshot. Full trial data →
- Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome NCT07247162 · Recruiting · Phase 4 · started 2026-08-26
- A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) NCT07441278 · Recruiting · Phase 2 · started 2026-09-28
- Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH) NCT07441200 · Recruiting · Phase 2 · started 2026-09-29
- An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) NCT07234032 · Recruiting · Phase 3 · started 2026-07-20
- A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2 NCT05737940 · Completed · Phase 2 · started 2023-04-24
- Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension NCT05968430 · Active Not Recruiting · Phase 3 · started 2023-07-14
- Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease NCT07473700 · Recruiting · Phase 2 · started 2026-10-30
- Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease NCT06449339 · Recruiting · Phase 4 · started 2024-07-17
- Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension NCT06205628 · Active Not Recruiting · Phase 1 · started 2024-03-21
- Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) NCT07179380 · Recruiting · Phase 3 · started 2026-01-07
- Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH) NCT07318597 · Recruiting · Phase 2 · started 2026-05-06
- A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037) NCT07600723 · Recruiting · Phase 4 · started 2026-10-08
- JX09 SAD/MAD in Healthy Participants NCT06183671 · Completed · Phase 1 · started 2024-01-18
- Low-Dose Spironolactone in Hemodialysis Patients With Resistant Hypertension NCT07888504 · Completed · Phase 4 · started 2024-08-20
- Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure NCT06507657 · Recruiting · Phase Early 1 · started 2024-12-12
How to read this
Evidence is graded on the tracker page in three tiers: clinical (tested in people), mechanistic (a documented action on the target) and correlative (an association in the literature). Most candidates sit in the lower tiers, and many trials are small or early-phase. The list is restricted to medicines and supplements: trial arms that are devices, procedures, behavioural programmes or measurements are filtered out automatically, so an occasional misclassified entry is possible; the tracker page lists every arm. The purpose of this list is to show where the research is, with sources, so that patients, clinicians and researchers can look further; it is not a ranking of what to take. How sources are chosen, graded and corrected is set out in our editorial policy.
More Cardiovascular notes
Related on this site
Research information, not medical advice. Decisions about any medicine belong with you and your clinician. The underlying data are open (CC BY 4.0) and refreshed daily; this note was generated from the tracker page on 28 October 2026.